Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A. (Q38164843)

30 August 2017

Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A. (English)

1 reference

30 August 2017

Christine Basmadjian

1

1 reference

30 August 2017

Frédéric Thuaud

series ordinal

2

1 reference

30 August 2017

Nigel Ribeiro

series ordinal

3

1 reference

30 August 2017

Laurent Désaubry

series ordinal

4

1 reference

30 August 2017

language of work or name

1 reference

1 December 2013

1 reference

Future Medicinal Chemistry

30 August 2017

1 reference

30 August 2017

5

1 reference

30 August 2017

2185-2197

1 reference

30 August 2017

18

1 reference

Rocaglamide derivatives are potent inhibitors of NF-kappa B activation in T-cells

30 August 2017

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae)

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Recent advances in the biology and chemistry of the flavaglines

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogen-activated protein kinase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Total synthesis of (±)-rocaglamide via oxidation-initiated Nazarov cyclization

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Enantioselective photocycloaddition of 3-hydroxyflavones: total syntheses and absolute configuration assignments of (+)-ponapensin and (+)-elliptifoline

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Prohibitin ligands in cell death and survival: mode of action and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Raf family kinases: old dogs have learned new tricks

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

eIF4F suppression in breast cancer affects maintenance and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Translational control in cancer etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Prohibitin and its rapidly emerging role as a biomarker of systemic malignancies-reply

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Prohibitin and its rapidly emerging role as a biomarker of systemic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta[b]benzofuran lignans isolated from Aglaia elliptica.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Next generation oncology drug development: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Novel flavaglines displaying improved cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Prohibitins and the cytoplasmic domain of CD86 cooperate to mediate CD86 signaling in B lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Prohibitin Induces the Transcriptional Activity of p53 and Is Exported from the Nucleus upon Apoptotic Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Inhibitors of translation initiation as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

Evidence for separate binding and scaffolding domains in the immunosuppressive and antitumor marine natural product, pateamine a: design, synthesis, and activity studies leading to a potent simplified derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.13.177

21 January 2018

Identifiers

DOI

10.4155/FMC.13.177

1 reference

30 August 2017

1 reference